X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Expansion of Antitumor Natural Killer Cells Using Anti-CD16 Antibody and Irradiated Autologous Peripheral Blood Mononuclear Cells

Yuvraj_pawp by Yuvraj_pawp
20th November 2017
in Europe, News

Natural killer (NK) cells are lymphocytes of the innate immune system and are important in controlling tumors and infections without depending on the recognition of specific antigens. The activation of NK cells occur via NK cell receptor interactions, including the CD 16 (Fc-gamma) receptors that bind antibodies (eg. IgG) attached to pathogens and infected cells. The CD16 receptor is involved in antibody-dependent cellular cytotoxicity, a process associated with the effectiveness of antibody-based cancer immunotherapies.

CD16 can induce NK cell activation without additional receptor signals; therefore, it can be used as a strategy to promote NK cell expansion. Various cytokines have been used to expand NK cells but without adequate effectiveness. Cancer cells lines have been used as feeder cells (used to nourish cultured tissue cells) for the large-scale expansion of NK cells. However, this requires methods to limit the growth of the feeder cells so that these do not contaminate the expanded NK cells.

To circumvent this issue, researchers instead used irradiated autologous peripheral blood mononuclear cells for large-scale expansion of purified cytotoxic NK cells activated with anti-CD16 monoclonal antibody. They exposed peripheral blood mononuclear cells to a radiation dose sufficient to inactivate T cells during NK expansion. The irradiated donor cells were then cultured with anti-CD16 antibody. This combination induced a stronger increase in expanded NK cells compared to irradiated cells alone. Further, flow cytometry analysis showed that the anti-CD16 and irradiated cell combination upregulated NK cell-activating receptors.

NK cells expanded via the combination method were found to secrete the cytokine INF-gamma after stimulation with target cancer cells (human cancer cell lines). Further, coculturing of target cancer cells with expanded NK cells led to increased target cell death. Tumor growth was suppressed in immunodeficient mice inoculated with lung and colon cancer cells after injection with NK cells expanded by the combination method. The results of these experiments demonstrate that NK cell expansion using anti-CD16 antibody and irradiated peripheral blood mononuclear cells can provide sufficient expansion of purified cytotoxic human NK cells with strong in vitro and in vivo antitumor activity and applicability to antitumor immunotherapy.

Lee, H., Son, C., Koh, E., Bae, J., Kang, C., Yang, K., & Park, Y. (2017). Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Scientific Reports, 7(1). doi:10.1038/s41598-017-09259-1

Previous Post

Sobi begins phase 3 study evaluating safety and efficacy of anakinra to treat Still’s disease

Next Post

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda in Europe

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Next Post

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda in Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In